Evidence map›Paper›PMID 34622227›Full record

Trial reportCell reports. Medicine2021

A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination.

Melissa M Lemke, Milla R McLean, Christina Y Lee, Ester Lopez, Emily R Bozich, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Sven Kratochvil, Bruce D Wines and 4 more

Open access · goldAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Regulatory Role of Fc Receptor in mIgMFrontiers in immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 3 countries.

Melissa M LemkeDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Milla R McLeanDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Christina Y LeeDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Ester LopezDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Emily R BozichDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Supachai Rerks-NgarmDepartment of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Punnee PitisuttithumVaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sorachai NitayaphanArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Sven KratochvilThe Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Bruce D WinesImmune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.
P Mark HogarthImmune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.
Stephen J KentDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Amy W ChungDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Kelly B ArnoldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · USMonash University · AUUniversity of Melbourne · AUArmed Forces Research Institute of Medical Science · THMahidol University · THMelbourne Sexual Health Centre · AUMinistry of Public Health · THPeter Doherty Institute · AURagon Institute of MGH, MIT and Harvard · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin G (IgG) antibodies that activate Fc-mediated immune functions have been correlated with vaccine efficacy, but it is difficult to unravel the relative roles of multiple IgG and Fc receptor (FcR) features that have the capacity to influence IgG-FcR complex formation but vary on a personalized basis. Here, we develop an ordinary differential-equation model to determine how personalized variability in IgG subclass concentrations and binding affinities influence IgG-FcγRIIIa complex formation and validate it with samples from the HIV RV144 vaccine trial. The model identifies individuals who are sensitive, insensitive, or negatively affected by increases in HIV-specific IgG1, which is validated with the addition of HIV-specific IgG1 monoclonal antibodies to vaccine samples. IgG1 affinity to FcγRIIIa is also prioritized as the most influential parameter for dictating activation broadly across a population. Overall, this work presents a quantitative tool for evaluating personalized differences underlying FcR activation, which is relevant to ongoing efforts to improve vaccine efficacy.

Indexed as

Precision MedicineSystems AnalysisVaccinationenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHumansImmunoglobulin GModels, BiologicalReceptors, FcReceptors, IgGReproducibility of Resultsenv Gene Products, Human Immunodeficiency VirusFCGR3A protein, humanHIV AntibodiesImmunoglobulin GReceptors, FcReceptors, IgGADCCFc receptorHIVIgGODE modelprecision medicineRV144sensitivity analysissystems serologyvaccine

Identifiers

PMID34622227
PMCPMC8484512
OpenAlexW3197582248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.